Pancreatic Cancer Research

ResearcherUniversidad San Pablo CEUActive in the last 2 years

Yolanda Quijano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-6626-591X; OpenAlex author ID A5044789539. Sources: OpenAlex.

Their work

Papers
13 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2013: 3 papers · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 13

  1. A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With N… Co-author DOI 10.1097/coc.0000000000001253↗
  2. A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation … Co-author DOI 10.1007/s12094-020-02287-w↗
  3. Prognostic Value of Lymph Node Status for Actual Long-Term Survival in Resected Pancreatic Cancer. Co-author PMID 32841360↗
  4. Venous Resection for Locally Advanced Pancreatic Cancer: Time Trend and Outcome Analysis of 65 Consecutive Resections at a High-Volume Center. First author DOI 10.1016/j.hpb.2022.05.919↗
  5. Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis. Co-author DOI 10.14701/ahbps.2019.23.2.200↗
  6. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2017.08.003↗
  7. Have the current and promising therapeutic options changed the surgeon's role in the treatment of pancreatic cancer? First author DOI 10.1590/0100-69912017001012↗
  8. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejso.2016.01.006↗
  9. Is arterial infiltration still a criterion for unresectability in pancreatic adenocarcinoma? First author DOI 10.1016/j.ciresp.2013.11.001↗
  10. Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. Co-author DOI 10.1038/bjc.2014.129↗
  11. A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer. Co-author DOI 10.1007/s10637-012-9822-x↗
  12. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/bjc.2013.415↗
  13. Alternative arterial reconstruction after extended pancreatectomy. Case report and some considerations of locally advanced pancreatic cancer. Co-author DOI 10.6092/1590-8577/1468↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Emilio Vicente · 12 shared papers, 2013–2026 · strength 0.95
  2. Antonio Cubillo · 6 shared papers, 2013–2026 · strength 0.49
  3. Riccardo R.C. Caruso · 7 shared papers, 2013–2020 · strength 0.46
  4. Benedetto Ielpo · 7 shared papers, 2013–2020 · strength 0.46
  5. Carlos Plaza Hernandezv · 7 shared papers, 2013–2020 · strength 0.43
  6. Hipólito J. Durán · 6 shared papers, 2013–2020 · strength 0.37
  7. Rafael Álvarez-Gallego · 2 shared papers, 2017–2026 · strength 0.31
  8. Berta Laquente · 1 shared paper, 2026 · strength 0.25
  9. Florian Castet · 1 shared paper, 2026 · strength 0.25
  10. Juli Busquets · 1 shared paper, 2026 · strength 0.25
  11. Teresa Mercade Macarulla · 1 shared paper, 2026 · strength 0.25
  12. Rafael Álvarez · 4 shared papers, 2013–2020 · strength 0.20
  13. Manuel M. Hidalgo · 4 shared papers, 2013–2016 · strength 0.15
  14. Jesús Rodríguez-Pascual · 3 shared papers, 2013–2014 · strength 0.10
  15. E. Barzola · 1 shared paper, 2019 · strength 0.09
  16. Carmen Rubio Rodríguez · 1 shared paper, 2020 · strength 0.09
  17. Xin Chen-Zhao · 1 shared paper, 2020 · strength 0.09
  18. Mariano Barbacid · 2 shared papers, 2013–2014 · strength 0.06
  19. Carmen E. Guerra · 2 shared papers, 2013–2014 · strength 0.06
  20. Almudena Moreno Elola-Olaso · 1 shared paper, 2014 · strength 0.04
  21. N.V. Rajeshkumar · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.